The recent ruling (21 November 2018) of the European Court of Justice puts an end to the dispute over the off-label use of bevacizumab for age-related macular degeneration.
Perspectives
Focus on
Inter-individual variability in drug response is one of the most relevant issues for the proper management of patients in clinical practice. The team of health professionals is faced with possible unexpected variations in individual responses to medicinal products responsible for therapeutic...
Columns
Drugs & Children
Preventing, detecting and treating pain is today an ethical imperative that strongly involves the paediatric world1,2. In hospital the measurement of pain should have the same relevance as that of the essential vital parameters and be constantly monitored at all the stages of hospital treatment....
From regulatory agencies
| 20 March 2019 EMA | 15 March 2019 EMA |
| 13 March 2019 AIFA | 07 March 2019 CADTH |
| 26 February 2019 AIFA | 26 February 2019 AIFA |
| 25 February 2019 FDA | 15 February 2019 EMA |
| 12 February 2019 AIFA | 08 February 2019 CADTH |